b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">28862715</PMID>\n        <DateCompleted>\n            <Year>2018</Year>\n            <Month>08</Month>\n            <Day>31</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2018</Year>\n            <Month>08</Month>\n            <Day>31</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Electronic">1724-6008</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>33</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>Jan</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>The International journal of biological markers</Title>\n                <ISOAbbreviation>Int. J. Biol. Markers</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Prognostic role of EZH2 in gliomas: a meta-analysis.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>62-67</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.5301/ijbm.5000293</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of this study was to elucidate the clinicopathological significance of enhancer of zeste homolog 2 (EZH2) expression in gliomas, including its incidence and prognostic role. In addition, we investigated the concordance between immunohistochemistry and polymerase chain reaction for determining the presence or absence of EZH2 in these tumors.</AbstractText>\n                <AbstractText Label="METHODS" NlmCategory="METHODS">The current meta-analysis included 1,049 gliomas with various WHO tumor grades from 12 eligible studies, which were analyzed for positivity of EZH2 and correlation between EZH2 expression and prognosis. Subgroup analyses were performed based on detection methods and WHO tumor grades.</AbstractText>\n                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We found the estimated positive rate of EZH2 in gliomas to be 0.663 (95% confidence interval [95% CI], 0.549-0.761). There was no difference between immunohistochemistry and polymerase chain reaction in determination of EZH2 positivity (0.706, 95% CI, 0.539-0.831 vs. 0.673, 95% CI, 0.472-0.825). The positive rate of EZH2 increased by increasing WHO tumor grade. EZH2 expression was significantly correlated with worse overall and progression-free survival (hazard ratio [HR] = 2.436, 95% CI, 1.350-4.393, and HR = 4.071, 95% CI, 1.325-12.508, respectively). The overall concordance rate between immunohistochemistry and polymerase chain reaction was 0.885 (95% CI, 0.300-0.993).</AbstractText>\n                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">EZH2 positivity was significantly correlated with WHO tumor grade and worse prognosis in gliomas.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Pyo</LastName>\n                    <ForeName>Jung-Soo</ForeName>\n                    <Initials>JS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>1 Department of Pathology, Eulji University Hospital, Eulji University School of Medicine, Daejeon - Republic of Korea.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>2 Study Group for Meta-Analysis, Eulji University Hospital, Eulji University School of Medicine, Daejeon - Republic of Korea.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kang</LastName>\n                    <ForeName>Dong-Wook</ForeName>\n                    <Initials>DW</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>1 Department of Pathology, Eulji University Hospital, Eulji University School of Medicine, Daejeon - Republic of Korea.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D017418">Meta-Analysis</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Int J Biol Markers</MedlineTA>\n            <NlmUniqueID>8712411</NlmUniqueID>\n            <ISSNLinking>0393-6155</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.1.1.43</RegistryNumber>\n                <NameOfSubstance UI="C498409">EZH2 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.1.1.43</RegistryNumber>\n                <NameOfSubstance UI="D000071221">Enhancer of Zeste Homolog 2 Protein</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000071221" MajorTopicYN="N">Enhancer of Zeste Homolog 2 Protein</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005910" MajorTopicYN="N">Glioma</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011379" MajorTopicYN="Y">Prognosis</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Concordance analysis</Keyword>\n            <Keyword MajorTopicYN="N">EZH2</Keyword>\n            <Keyword MajorTopicYN="N">Glioma</Keyword>\n            <Keyword MajorTopicYN="N">Meta-analysis</Keyword>\n            <Keyword MajorTopicYN="N">Prognosis</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2017</Year>\n                <Month>9</Month>\n                <Day>2</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2018</Year>\n                <Month>9</Month>\n                <Day>1</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2017</Year>\n                <Month>9</Month>\n                <Day>2</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">28862715</ArticleId>\n            <ArticleId IdType="pii">3E6531A5-B6B1-498C-B528-CB6B3AE07651</ArticleId>\n            <ArticleId IdType="doi">10.5301/ijbm.5000293</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'